JG
MLTX icon

Jefferies Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jefferies Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$525K Buy
+67,654
New +$478K ﹤0.01% 1022
2022
Q1 		– Sell
-78,308
Closed -$774K – 1798
2021
Q4 		$774K Buy
+78,308
New +$778K ﹤0.01% 1069

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jefferies Group's MLTX Position: Q3 2022 in Review

Jefferies Group opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2022: 67,654 shares worth $525K. The stake represents ﹤0.01% of the portfolio and ranks #1022 among its holdings. This is a return to the name: Jefferies Group previously reported a position in MLTX as recently as Q4 2021.

Jefferies Group first reported a position in MLTX in Q4 2021 and has held it in 2 quarters since. The position peaked at $774K in Q4 2021. 24 funds tracked by Wall St. Rank hold MLTX as of Q3 2022.

  • Jefferies Group held 67,654 shares of MoonLake Immunotherapeutics worth $525K as of Q3 2022.
  • MoonLake Immunotherapeutics was a new Jefferies Group position in Q3 2022.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1022 holding.
  • Jefferies Group first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 2 quarters since.
  • Jefferies Group's MoonLake Immunotherapeutics position peaked at $774K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.